Clarity Pharmaceuticals is an Australian clinical-stage radiopharmaceutical company focused on oncology. It develops targeted copper theranostics based on its SAR Technology platform.
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
Another participant with metastatic castration-resistant prostate cancer achieved undetectable PSA and negative PSMA PET after treatment with 67Cu-SAR-bisPSMA in the SECuRE trial. This marks the fifth patient to achieve undetectable disease by radiographic assessment in Clarity Pharmaceuticals' program.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05286840 |
64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer |
UNKNOWN | PHASE1/PHASE2 |
